• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
A new Emory University study reveals why a once-promising experimental amyotrophic lateral sclerosis (ALS) drug, despite successfully reaching its intended target in the central nervous system (CNS)—the brain and spinal cord—failed to help patients.
Specifically, the researchers found that PTDSS1 deficiency not only enhanced tumor cells' responsiveness to interferon-γ (IFN-γ) but also increased antigen presentation (e.g., elevated MHC-I expression), making tumor cells more susceptible to antigen-specific CD8+ T cell recognition and killing. Furthermore, PTDSS1 deficiency improved the tumor microenvironment (TME), increasing the number of tumor-infiltrating CD8+ T cells and the frequency of iNOS-positive myeloid cells. Genetic and pharmacological interventions confirmed that both PTDSS1 knockdown and PTDSS1 inhibitors enhanced the efficacy of PD-1 inhibitors, suppressed tumor burden, and prolonged overall survival in mice. The related research was published in Science Advances.
Chronic pain affects approximately one in five adults, significantly negatively impacting quality of life and leading to severe socioeconomic consequences. In fact, when all pain conditions are considered, chronic pain is the leading cause of disability worldwide. Unfortunately, current treatments for chronic pain are often suboptimal due to poor efficacy and tolerability. The molecular causes of chronic pain are not fully understood, but increased excitability of nociceptors and the central pain pathways to which they project are important factors contributing to this state of pain sensitization.
In the field of medical research, leukemia remains a major threat to human health. Acute myeloid leukemia (AML), a member of the leukemia family, presents a heavy burden on countless patients and their families with its complex and diverse subtypes and aggressive disease progression. Among these, acute megakaryocytic leukemia (AMKL), due to its rarity and highly aggressive nature, remains a pressing challenge for the medical community.
To overcome these challenges, researchers have continuously upgraded and modified CAR-T cells. For example, incorporating different costimulatory signaling domains, such as CD28 or 4-1BB, addresses the short in vivo survival and poor activity of CARs. Simultaneously incorporating two costimulatory molecules into third-generation CARs enhances cytokine secretion. To better target the tumor microenvironment, researchers have developed fourth-generation CAR-T cells—"armored" T cells.
Have you ever wondered why some people seem naturally immune to certain bacterial infections? Or why do some recover quickly even after exposure to viruses? The answer may be a mysterious group of immune cells in our bodies called B-1a cells. For a long time, scientists have even debated whether humans actually possess these cells.
T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematologic malignancy, accounting for approximately 15% of childhood acute lymphoblastic leukemia (ALL) and 25% of adult ALL. While cure rates for pediatric patients can reach 80%, the long-term survival rate for adult patients remains below 40%. More concerningly, more than half of patients relapse after treatment or fail to respond to standard therapy, with the median overall survival for relapsed/refractory T-ALL being only approximately eight months. Current treatment options primarily rely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT). However, these treatments are associated with significant toxicity and high failure rates, necessitating an urgent need for safer and more effective targeted therapy strategies.
Have you ever wondered why certain cancers caused by the human papillomavirus (HPV) are so stubborn, even defying advanced immunotherapies? HPV-related cancers kill over 300,000 people worldwide each year, with cervical and head and neck cancers being particularly common. While HPV vaccines have been highly successful in preventing these diseases, treatment options for established HPV-positive tumors remain limited. In recent years, scientists have gradually realized that immune defection within the tumor microenvironment (TME) may be the key.
Breast cancer is one of the most common malignancies in women worldwide, with approximately 70% of cases being estrogen receptor-positive (ER+) subtypes. In recent years, CDK4/6 inhibitors (such as palbociclib) combined with endocrine therapy (such as tamoxifen) have become first-line treatment options for ER+ breast cancer, significantly prolonging progression-free survival. However, with widespread clinical application, drug resistance has become increasingly prominent, with approximately 30%-50% of patients experiencing disease progression after 2-3 years of treatment. The mechanisms of drug resistance are complex and diverse, including Rb protein loss and Cyclin E1 amplification, but the causes of resistance in a large number of cases remain unclear.
The median survival of patients with advanced pancreatic ductal adenocarcinoma (PDAC) is less than one year, highlighting the urgent need for treatment advances. Recently, a research paper titled "Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer" was published in Cell Reports Medicine, a subsidiary of Cell. The paper reported a phase 1 clinical trial evaluating the safety and efficacy of anti-MSLN CAR-T cell therapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Results showed that the CAR-T cell therapy was well tolerated but not highly effective. The research team further demonstrated in mouse studies that simultaneous knockout of both ID3 and SOX4 in these CAR-T cells improved long-term relapse-free survival.
